Benefits
Cholesterol: positive in older Indian trials, null to adverse in the Western trials
The Indian trial cited most often (Singh 1994, 61 patients, 24 weeks, 100 mg of guggulipid per day) reported drops of 11.7% in total cholesterol, 12.5% in LDL and 12.0% in triglycerides from post-diet baseline in the guggulipid group, with the placebo group unchanged. Two things limit how much weight that carries. The figures are within-group changes rather than a between-group comparison, and the Moradabad research group that produced them was the subject of a decade-long BMJ investigation, with expressions of concern published by both the BMJ and The Lancet in July 2005; none of the group's papers has been retracted. No Western trial has reproduced the result: in 103 US adults LDL rose 9% to 10% relative to placebo, in 43 Norwegian adults LDL did not change, and in 90 Italian adults given guggul with triphala LDL fell 4.8% against 4.9% on placebo. A 2021 meta-analysis pooling 7 trials and 380 people still reports a net LDL reduction, but it mixes these conflicting trials together with three quarters of the variation between them unexplained, and its positive signal comes from the older studies rather than the rigorous ones.
Joint symptoms: no controlled trial has ever been run
A PubMed search for randomized or placebo-controlled human studies of guggul, guggulipid or Commiphora on arthritis, joint or knee outcomes returns no trial of guggul on its own. The hits are a Boswellia serrata extract, a Korean multi-herb product, an extract of Commiphora myrrha (a different species), and multi-herb Ayurvedic compounds from which nothing can be attributed to guggul. The only human data specific to guggul are a 2001 case report and a 2003 open-label study in 30 people with knee osteoarthritis given 500 mg three times daily, both from the same research group. That study had no placebo arm, and knee osteoarthritis pain improves substantially on placebo, so it cannot show that guggul did anything.
Thyroid: unchanged when measured in people, with adverse reports in one trial
The thyroid claim rests on a single 1984 study in albino rats, in which Z-guggulsterone raised thyroid iodine uptake and thyroid peroxidase activity. It has not carried over to people. The US randomized trial measured thyroid function in 103 adults with a sensitive third-generation TSH assay and found no significant change, and its authors raised this directly when explaining why guggulipid failed to lower LDL. The only other human thyroid data are adverse: 2 of 18 people taking guggul in the Norwegian randomized trial reported possible thyroid problems. If you have a thyroid condition or take levothyroxine, treat this as a reason for caution rather than a benefit.
Skin: one small 1994 trial, never replicated
One randomized trial from 1994 gave 20 people with nodulocystic acne either tetracycline 500 mg twice daily or gugulipid tablets equivalent to 25 mg guggulsterone twice daily, for 3 months. Inflammatory lesions fell 68% with gugulipid and 65.2% with tetracycline, a difference that was not statistically significant. At three months of follow-up 2 people on gugulipid and 4 on tetracycline had relapsed. Twenty patients split between two arms, with no placebo group and no repeat of the study in the thirty years since, cannot settle whether it works. It is nevertheless the only positive randomized result on this page that a later trial has not contradicted.
Mechanism of action
Farnesoid X receptor antagonism
Guggulsterones antagonize the farnesoid X receptor (FXR), a bile-acid-activated nuclear receptor central to cholesterol and bile acid homeostasis. This is the leading proposed mechanism behind the cholesterol-lowering claims, and it did not translate: both Western randomized trials found no LDL reduction, and in mice gugulipid raised cholesterol, caused endothelial dysfunction, increased atherosclerosis and shortened survival. Guggulsterones are also agonists of the pregnane X receptor, a separate property that matters clinically because PXR activation induces CYP3A drug-metabolising enzymes.
Thyroid hormone modulation
A 1984 study found that Z-guggulsterone raised thyroid iodine uptake and thyroid peroxidase activity in albino rats. The idea that this would speed LDL clearance was tested directly in the US randomized trial, which measured TSH with a sensitive third-generation assay in 103 adults and found no significant change. Taken with the 2 reports of possible thyroid problems in the Norwegian trial, this is a caution rather than a proposed benefit.
Anti-inflammatory NF-κB modulation
Guggulsterones inhibit NF-κB-dependent inflammatory signalling in cell culture. The one human trial that measured an inflammatory marker found no significant effect: in the US randomized trial the high dose lowered median hs-CRP by 29% against a 25% rise on placebo, but the comparison did not reach significance (P=.10). No joint outcome has been measured against a control at all, so this remains a laboratory observation rather than a reason to expect a joint effect.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 103 ambulatory adults with hypercholesterolemia in Philadelphia, comparing 1,000 mg or 2,000 mg of guggulipid standardized to 2.5% guggulsterones taken three times daily (3,000 or 6,000 mg per day) against matching placebo for 8 weeks on a typical Western diet. Primary outcome was percentage change in directly measured LDL; secondary outcomes were total cholesterol, HDL, triglycerides, VLDL and laboratory safety measures. Funded in part by Sabinsa, the supplier of the branded extract.
103 US adults with hypercholesterolemia; 8-week intervention.
Negative on the primary endpoint and adverse in direction. LDL fell 5% on placebo (n=36) but rose 4% on the standard dose (n=33, P=.01 versus placebo) and 5% on the high dose (n=34, P=.006 versus placebo), a net change of plus 9% to plus 10%. Both doses raised LDL, not only the lower one, though the apparent dose relation was not itself statistically significant. Total cholesterol, HDL, triglycerides and VLDL did not change significantly in the intention-to-treat analysis, and there was no significant effect on body weight, on TSH measured with a sensitive third-generation assay, or on liver enzymes, kidney function or electrolytes. Six participants taking guggulipid developed a hypersensitivity rash compared with none on placebo (P=.02), 5 of them on the high dose. The authors concluded that guggulipid did not appear to improve serum cholesterol and might in fact raise LDL, and that it appeared to cause a dermatologic hypersensitivity reaction in some patients.
Randomized, double-blind trial of guggulipid 50 mg twice daily (100 mg per day, with guggulsterone content not stated in the paper) as an adjunct to a fruit and vegetable enriched prudent diet, in 61 Indian patients with hypercholesterolemia (31 guggulipid, 30 placebo) over 24 weeks. Outcomes: total cholesterol, LDL, triglycerides, total-to-HDL ratio, lipid peroxides. Because the paper does not state the guggulsterone content, this product cannot be compared on dose with the US trial, which delivered 75 to 150 mg of guggulsterones per day.
61 Indian adults with hypercholesterolemia; 24-week intervention.
Total cholesterol fell 11.7%, LDL 12.5%, triglycerides 12.0% and the total-to-HDL ratio 11.1% from post-diet baseline within the guggulipid group, with the placebo group unchanged; lipid peroxides fell 33.3%. Note that these are within-group changes from baseline, not a between-group difference, which the paper does not report. HDL did not change in either group. Two later Western randomized trials found no LDL benefit. Read this result with care for a further reason: the Moradabad centre that ran it was the subject of a decade-long BMJ investigation into its research, and both the BMJ and The Lancet published expressions of concern in July 2005. None of the group's papers has been retracted.
Double-blind, randomized, placebo-controlled trial in Norwegian general practice. 43 women and men aged 27 to 70 with moderately raised cholesterol took 2,160 mg per day of a guggul-based formulation (4 capsules) or placebo for 12 weeks. Two dropouts, one withdrawal and incomplete laboratory results for six people left 34 with complete data (18 guggul, 16 placebo). Lipids measured at baseline, 6 weeks and 12 weeks.
43 Norwegian adults aged 27 to 70 with moderately raised cholesterol; 12-week intervention, 34 analysed.
LDL, triglycerides and the total cholesterol to HDL ratio did not differ between the groups. Total cholesterol and HDL were both significantly lower on guggul than on placebo, and the authors wrote that the clinical magnitude of this remains obscure, since a fall in HDL is not a desirable direction. Side effects were more common on guggul (10 of 18 versus 4 of 16): mild gastrointestinal discomfort in 7, possible thyroid problems in 2, and a generalised skin rash in 1, who withdrew from the trial. Side effects were more common on guggul, and the authors concluded that more and larger studies are needed to establish effects and safety.